Leading Edge Pharms Opens CBD Research and Innovation Center, LENCURA Labs

Tuesday, March 26, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

Leading Edge Pharms CSO Dr. Daniel Holsworth to Oversee R&D

HENDERSON, Nevada, March 26, 2019 /PRNewswire/ -- Leading Edge Pharms, Inc., (LEP) a biotechnology company developing

novel cannabinoid therapies and innovative delivery systems, today announced the opening of the LENCURA Labs™ Research and Innovation Center in Carlsbad, CA. The investment includes advanced organic medical chemists, research instruments and equipment dedicated to accelerating Leading Edge Pharms' technical expertise and new product development.

"We believe cannabinoids are the medical science market of the future," said Dr. Daniel Holsworth, Chief Science Officer of LEP. "By enhancing our platform with R&D capabilities and key partner alliances, LEP is now well-positioned to implement clinical studies to target specific medical conditions and demonstrate the efficacy of new cannabinoid therapies and delivery systems. Through research testing in animal models, cellular lines, and human trials, LENCURA Labs will directly add further value in support of our product innovations that have the potential to improve millions of lives and unlock applications for many poorly-treated maladies."

LENCURA Labs will allow LEP to leverage a growing inventory of intellectual property in neuroscience and pain. LEP's R&D activities will focus on the development of safe and effective topical cannabinoid formulations as a step-wise approach to pain management therapy.

David Chadwick, Chief Executive Officer of LEP said, "Our goal is to advance the development of proprietary cannabinoid products. I am confident that the new lab will allow us to optimize our existing product offerings and take product development to new heights. We believe the clinical work that will drive innovation at LENCURA Labs may soon be used to help tackle some of the largest public health problems of our time, including the opioid drug epidemic."

ABOUT LEADING EDGE PHARMS, INC.

Leading Edge Pharms, Inc. (LEP) is a biotechnology company focused on the research, development and commercialization of novel cannabinoid therapies and innovative delivery platforms. LEP is the developer of CANNAVERA™ pain relief products, available in pharmacies across the United States. All LEP products are manufactured in FDA registered facilities adhering to current Good Manufacturing Practices and are available at www.LENCURA.com.

Learn more at www.leadingedge.com. Follow Leading Edge Pharms on LinkedIn and Twitter.

Leading Edge Pharms Company Contact:        David Chadwick, CEOdchadwick@leadingedge.com +1(800)813-0013

Leading Edge Pharms Media Contact:Nicole Grubnerleadingedge@finnpartners.com+1(929)222-8011

Cision View original content:http://www.prnewswire.com/news-releases/leading-edge-pharms-opens-cbd-research-and-innovation-center-lencura-labs-300818573.html

SOURCE Leading Edge Pharms, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store